U.S. Hospitality Stock News

Thinking about whether Tencent Music Entertainment Group is a bargain or just riding the hype? You are not alone, as there is plenty to unpack behind the price tag. Recent stock performance has been impressive, jumping 63% so far this year and 63.7% over the past 12 months, despite a volatile 30-day window with a decline of nearly 20%. Headlines have shone a spotlight on the company’s expansion moves, including new licensing deals with global music giants and strategic...

Mastercard (MA) is pushing further into the digital assets space, recently increasing development of stablecoin infrastructure and blockchain solutions. The company’s latest collaborations aim to support real-time cross-border settlements and expand the reach of self-custody wallet capabilities. See our latest analysis for Mastercard. Mastercard’s latest push into digital assets comes against a backdrop of steady operational execution and a strong long-term performance. While recent 90-day...

In November 2025, DXC Technology achieved a significant milestone by migrating over two million property and casualty policies for Brethren Mutual to its modern DXC Assure P&C Policy platform, while also earning recognition as International Transformation Partner at the 2025 Global Technology Excellence Awards and expanding its SAP capabilities in the Middle East, Africa, and Japan. These developments highlight DXC’s ongoing commitment to innovation, digital transformation leadership, and...

On November 21, 2025, Public Service Company of Colorado, a wholly owned subsidiary of Xcel Energy Inc., filed an electric rate case with the Colorado Public Utilities Commission, seeking a US$356 million revenue increase to help recover costs for extending operations at Comanche Unit 2. This filing introduces potential changes to Xcel Energy’s revenue and operational outlook in Colorado, reliant on regulatory review and approval expected by the third quarter of 2026. We’ll now examine how...

In the past week, AbbVie announced that Canada's Drug Agency recommended reimbursement for SKYRIZI in ulcerative colitis and concluded pricing negotiations, expanding access for adults with moderate to severe disease who have had limited treatment success. This update underscores AbbVie's ongoing progress in advancing immunology treatments and increasing its reach in key international markets. We'll now examine how expanded public access for SKYRIZI in Canada could affect AbbVie's investment...

Northwest Bancshares (NWBI) has come into focus among regional banks following its latest performance numbers. Investors are weighing steady revenue and net income growth in light of mixed returns over the past year and recent price moves. See our latest analysis for Northwest Bancshares. After a choppy start to the year, Northwest Bancshares' share price has steadied in recent weeks, recovering 2.05% over the past month following earlier losses. While the 1-year total shareholder return is...

Exelon Corporation recently announced the preliminary approval of a proposed settlement in a consolidated shareholder derivative lawsuit, resolving claims of fiduciary breaches and introducing new governance reforms, with US$40 million from insurers supporting these actions. This comprehensive resolution follows an in-depth, multi-year investigation and involves the company implementing lasting corporate governance changes aimed at strengthening oversight and accountability. Now, we'll...

Curious whether Tennant stock is a truly undervalued opportunity hiding in plain sight? You’re not alone. Let’s dig into what the numbers and broader trends really say about its value. After climbing 2.0% this past week, Tennant’s shares have still slipped 8.7% over the last month and are down 16.0% in the past year. This comes despite a steady gain of 18.3% over three years and 12.7% over five years. Recent headlines have focused on Tennant’s strategic investment in automation technologies...

Amphenol (APH) has caught the attention of investors recently, trading higher over the past month. With steady growth in both revenue and net income, the stock continues to show resilience in the tech sector. See our latest analysis for Amphenol. Momentum around Amphenol has been picking up, with the share price climbing over 29% in the last three months and an impressive 104% gain year-to-date. The stock’s long-term record is just as notable, with total shareholder returns surpassing 95%...

FinVolution Group recently reported its third quarter 2025 earnings, posting revenue of CNY 3,486.61 million and net income of CNY 624.29 million, along with updated guidance projecting full-year 2025 revenue between RMB 13.1 billion and RMB 13.7 billion. The company also completed a share repurchase program, buying back a total of US$36.56 million in shares since March 2025. We'll examine how FinVolution's revised revenue guidance and steady earnings outlook may reshuffle its long-term...

Aramark revealed several updates that caught investors' attention this week. These include its latest annual 10-K filing, new fiscal 2026 revenue guidance, and a 14% boost to its quarterly dividend payout. See our latest analysis for Aramark. Aramark’s recent moves, including a major segment divestiture and the launch of advanced hospitality solutions, landed just as its stock has struggled to maintain upward momentum. While the past twelve months show a total shareholder return of -7.7%, its...

Wondering if KeyCorp might be a hidden value pick in today’s banking sector? Let’s dig in together and see if it deserves a spot on your radar. The stock has climbed 3.1% in the past week and is up 5.6% over the last month, signaling renewed investor interest and a possible shift in risk appetite. Recent headlines highlight industry-wide optimism as key U.S. banks benefit from improved economic outlooks and stabilizing interest rates. KeyCorp in particular has been mentioned for its...

Curious if TransMedics Group is still a bargain or if the huge price moves have put it out of reach? Let’s break down whether now is the right time to buy in or stay on the sidelines. TransMedics stock has soared 120.0% year-to-date and 68.7% over the past year, drawing fresh attention from growth investors and those tracking emerging medical technology trends. Much of this renewed interest follows industry headlines about innovations in organ transplant logistics and successful expansion...

Construction Partners, Inc. recently reported strong earnings results for the fourth quarter and full year ended September 30, 2025, with quarterly sales rising to US$899.85 million and net income reaching US$56.57 million. The company also reaffirmed its guidance for fiscal year 2026, projecting revenue between US$3.4 billion and US$3.5 billion and net income of US$150 million to US$155 million, reflecting management’s confidence in continued growth. We’ll explore how these robust financial...

In the past week, several leading investment banks and analysts revised their ratings and outlooks for Conagra Brands, signaling a reassessment of the company's prospects in the consumer packaged foods sector. This wave of new analyst commentary highlights increasing uncertainty around the company's future performance despite its broad market presence and operational strengths. We'll examine how this renewed analyst caution could affect Conagra Brands' investment narrative and market...

Solventum (SOLV) has set the stage for fresh investor attention by announcing a major share repurchase program. The Board approved a buyback of up to $1,000 million, which signals confidence in the company’s future direction. See our latest analysis for Solventum. Solventum’s momentum has picked up following its recently announced $1 billion buyback, a move that is catching investor attention. The company also made a noteworthy appearance at MEDICA 2025 in Germany, reinforcing its presence in...

EyePoint Pharmaceuticals recently announced that the independent Data Safety Monitoring Committee completed its second scheduled review of the pivotal Phase 3 trial for DURAVYU, an investigational sustained-release therapy for wet age-related macular degeneration (wet AMD). This review highlights DURAVYU's potential to offer a differentiated, long-acting treatment option for both wet AMD and diabetic macular edema (DME), addressing therapeutic needs in these growing patient...

Earlier this quarter, Carillon Tower Advisers highlighted Alnylam Pharmaceuticals after the company's launch of vutrisiran for transthyretin amyloidosis surpassed expectations, leading Alnylam to significantly raise its sales guidance for the therapy. This upward revision in sales projections was driven by stronger-than-forecast demand, underlining Alnylam's expanding leadership in gene-silencing therapies for rare diseases. We'll explore how Alnylam's raised guidance for its transthyretin...

Xenia Hotels & Resorts (XHR) just released its third quarter results. The company reported funds from operations that met expectations, while revenue fell a bit short of forecasts. Management struck a careful tone for the months ahead and lowered expectations for Q4 performance. See our latest analysis for Xenia Hotels & Resorts. Xenia Hotels & Resorts’ share price has staged a solid recovery over the past month, climbing nearly 10%. However, it is still trailing for the year with a -5% total...

Royalty Pharma recently reported a strong third quarter, with portfolio receipts rising by 11% to US$814 million and updated its full-year guidance for 2025 to reflect further growth, following the announcement by the company that its CFO sold US$2.68 million in shares through a pre-arranged plan. An interesting insight is that while short interest in Royalty Pharma’s stock increased, it remains below the industry average, pointing to relatively lower bearish sentiment from investors...

Getty Realty (GTY) announced it will issue $250 million in senior unsecured notes at a fixed 5.76% rate. The notes are set to fund in January 2026. This financing move will help repay existing credit facility balances and support future investments. See our latest analysis for Getty Realty. Getty Realty’s recent debt financing comes at a time when its share price momentum has been muted. The company posted a 2.48% one-month share price return but experienced a 3.75% decline year-to-date. Over...

National Vision Holdings (EYE) laid out an ambitious plan for the next five years, highlighting a disciplined investment approach, a phased transformation, and significant store expansion. The company also reaffirmed its fiscal 2025 earnings outlook. Investors now have a clearer view of management's roadmap through 2030. See our latest analysis for National Vision Holdings. National Vision Holdings’ bold transformation plans come amid strong momentum for the stock, with a 167.9% share price...

If you have ever wondered whether Kohl's stock offers good value or if the recent buzz is just noise, you are not alone. Let’s dive into what is actually happening with the share price. Kohl’s has caught the market’s attention by surging a remarkable 56.5% in the past week and boasting a 75.3% return year-to-date, signaling shifting sentiment or renewed growth potential. Much of this momentum has been linked to industry chatter around M&A interest and potential strategic shifts in the retail...

La-Z-Boy Incorporated recently announced second-quarter earnings, reporting sales of US$522.48 million and net income of US$28.86 million, alongside a 10% increase in its quarterly dividend and new guidance for third-quarter sales between US$525 million and US$545 million. An interesting detail is that this marks the fifth consecutive year of double-digit dividend increases, reflecting the company’s ongoing transformation and growing confidence in its operational improvements and expansion...